BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23313142)

  • 21. Ars2 is overexpressed in human cholangiocarcinomas and its depletion increases PTEN and PDCD4 by decreasing microRNA-21.
    He Q; Cai L; Shuai L; Li D; Wang C; Liu Y; Li X; Li Z; Wang S
    Mol Carcinog; 2013 Apr; 52(4):286-96. PubMed ID: 22213145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma.
    Terashi T; Aishima S; Taguchi K; Asayama Y; Sugimachi K; Matsuura S; Shimada M; Maehara S; Maehara Y; Tsuneyoshi M
    Liver Int; 2004 Feb; 24(1):38-45. PubMed ID: 15101999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis.
    Meng F; Han Y; Staloch D; Francis T; Stokes A; Francis H
    Hepatology; 2011 Nov; 54(5):1718-28. PubMed ID: 21793031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma.
    Obama K; Ura K; Li M; Katagiri T; Tsunoda T; Nomura A; Satoh S; Nakamura Y; Furukawa Y
    Hepatology; 2005 Jun; 41(6):1339-48. PubMed ID: 15880566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma.
    Aishima S; Taguchi K; Terashi T; Matsuura S; Shimada M; Tsuneyoshi M
    Mod Pathol; 2003 Oct; 16(10):1019-27. PubMed ID: 14559985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between pancreatic secretory trypsin inhibitor and early recurrence of intrahepatic cholangiocarcinoma following surgical resection.
    Tonouchi A; Ohtsuka M; Ito H; Kimura F; Shimizu H; Kato M; Nimura Y; Iwase K; Hiwasa T; Seki N; Takiguchi M; Miyazaki M
    Am J Gastroenterol; 2006 Jul; 101(7):1601-10. PubMed ID: 16863567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma.
    He F; Yan Q; Fan L; Liu Y; Cui J; Wang J; Wang L; Wang Y; Wang Z; Guo Y; Huang G
    Hum Pathol; 2010 Mar; 41(3):415-24. PubMed ID: 19954816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.
    Farazi PA; Zeisberg M; Glickman J; Zhang Y; Kalluri R; DePinho RA
    Cancer Res; 2006 Jul; 66(13):6622-7. PubMed ID: 16818635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of PDGFA and its receptor during carcinogenesis of Opisthorchis viverrini-associated cholangiocarcinoma.
    Boonjaraspinyo S; Wu Z; Boonmars T; Kaewkes S; Loilome W; Sithithaworn P; Nagano I; Takahashi Y; Yongvanit P; Bhudhisawasdi V
    Parasitol Int; 2012 Mar; 61(1):145-50. PubMed ID: 21777692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced expression of mucin 6 glycoprotein in cholangiocarcinoma tissue from patients in Thailand as a prognostic marker for survival.
    Thuwajit P; Chawengrattanachot W; Thuwajit C; Sripa B; Paupairoj A; Chau-In S
    J Gastroenterol Hepatol; 2008 May; 23(5):771-8. PubMed ID: 18410610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heparanase expression at the invasion front of human head and neck cancers and correlation with poor prognosis.
    Beckhove P; Helmke BM; Ziouta Y; Bucur M; Dörner W; Mogler C; Dyckhoff G; Herold-Mende C
    Clin Cancer Res; 2005 Apr; 11(8):2899-906. PubMed ID: 15837740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metallothionein overexpression and its prognostic relevance in intrahepatic cholangiocarcinoma and extrahepatic hilar cholangiocarcinoma (Klatskin tumors).
    Schmitz KJ; Lang H; Kaiser G; Wohlschlaeger J; Sotiropoulos GC; Baba HA; Jasani B; Schmid KW
    Hum Pathol; 2009 Dec; 40(12):1706-14. PubMed ID: 19683330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.
    Aishima S; Asayama Y; Taguchi K; Sugimachi K; Shirabe K; Shimada M; Sugimachi K; Tsuneyoshi M
    Mod Pathol; 2002 Nov; 15(11):1181-90. PubMed ID: 12429797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type.
    Shibahara H; Tamada S; Higashi M; Goto M; Batra SK; Hollingsworth MA; Imai K; Yonezawa S
    Hepatology; 2004 Jan; 39(1):220-9. PubMed ID: 14752841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The expression of HSP27 is associated with poor clinical outcome in intrahepatic cholangiocarcinoma.
    Romani AA; Crafa P; Desenzani S; Graiani G; Lagrasta C; Sianesi M; Soliani P; Borghetti AF
    BMC Cancer; 2007 Dec; 7():232. PubMed ID: 18154639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathologic features in patients with long-term survival following resection for intrahepatic cholangiocarcinoma.
    Uenishi T; Hirohashi K; Kubo S; Yamamoto T; Yamazaki O; Shuto T; Tanaka H; Kinoshita H
    Hepatogastroenterology; 2003; 50(52):1069-72. PubMed ID: 12845984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survival.
    Keeratichamroen S; Leelawat K; Thongtawee T; Narong S; Aegem U; Tujinda S; Praditphol N; Tohtong R
    Int J Oncol; 2011 Oct; 39(4):873-81. PubMed ID: 21687942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma.
    Nishino R; Honda M; Yamashita T; Takatori H; Minato H; Zen Y; Sasaki M; Takamura H; Horimoto K; Ohta T; Nakanuma Y; Kaneko S
    J Hepatol; 2008 Aug; 49(2):207-16. PubMed ID: 18490072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serosal invasion in TNM staging of mass-forming intrahepatic cholangiocarcinoma.
    Uenishi T; Yamazaki O; Yamamoto T; Hirohashi K; Tanaka H; Tanaka S; Hai S; Kubo S
    J Hepatobiliary Pancreat Surg; 2005; 12(6):479-83. PubMed ID: 16365823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression and prognostic value of PRL-3 in human intrahepatic cholangiocarcinoma.
    Xu Y; Zhu M; Zhang S; Liu H; Li T; Qin C
    Pathol Oncol Res; 2010 Jun; 16(2):169-75. PubMed ID: 19757198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.